ArcherDx company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

archerdx.com

Founded Year

2013

Stage

Acquired - II | Acquired

Total Raised

$150M

Valuation

$0000 

About ArcherDx

ArcherDX offers a bioinformatics platform for targeted sequencing applications featuring proprietary Anchored Multiplexed PCR (AMP) chemistry in a lyophilized format.On June 22nd, 2020, ArcherDx was acquired by Invitae at a valuation between $325 and $1400M.

ArcherDx Headquarter Location

2477 55th Street Suite 202

Boulder, Colorado, 80301,

United States

877-771-1093

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ArcherDx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ArcherDx is included in 6 Expert Collections, including Cancer.

C

Cancer

105 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

M

Medical Devices

8,592 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

13,075 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health Monitoring & Diagnostics

76 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx

H

Health IT

7,900 items

ArcherDx Patents

ArcherDx has filed 18 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/2/2017

3/16/2021

Molecular biology, Clusters of differentiation, Immune system, Immunology, DNA

Grant

Application Date

11/2/2017

Grant Date

3/16/2021

Title

Related Topics

Molecular biology, Clusters of differentiation, Immune system, Immunology, DNA

Status

Grant

Latest ArcherDx News

PureTech Founded Entity Akili Announces Veteran Life Sciences Executive Matt Franklin in Newly Created Role of President and Chief Operating Officer

Jun 6, 2022

Franklin brings proven track record leading early commercialization and growing disruptive healthcare business models, including at Exact Sciences, Foundation Medicine and Boston Scientific Franklin to oversee Akili’s Commercial, Product, Engineering, Medical and People Operations, reporting to CEO Eddie Martucci June 06, 2022 07:05 AM Eastern Daylight Time BOSTON--( BUSINESS WIRE )-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. (“Akili”), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced that industry veteran Matt Franklin will join the company in the newly created role of President and Chief Operating Officer, effective June 21, 2022. As President and COO, Franklin will join Eddie Martucci, Akili’s Chief Executive Officer, and the company’s executive leadership team to scale the organization and bring Akili’s diverse pipeline of cognitive treatments to market, with an initial focus on the commercial launch of EndeavorRx®. He will lead the day-to-day operations of the company, and oversee Commercial, Product, Engineering, Medical and People Operations. Franklin brings more than two decades of experience across business, commercial and strategic marketing in the diagnostics, life sciences and technology industries leading and evolving innovation. Most recently, Franklin served as General Manager of the Precision Oncology business unit at Exact Sciences. Previously, Franklin was the Chief Commercial Officer at Thrive Earlier Detection Corp, where he led the go-to-market strategy development for their ground-breaking multi-cancer early detection assay. In addition, Franklin served as the Chief Business Officer for ArcherDX, a growth-stage molecular diagnostics company, where he was responsible for establishing and scaling the global sales, customer support, marketing, market access, business development and corporate development teams. Prior to ArcherDX, Franklin served as the Senior Vice President of Global Marketing and Clinical Product Strategy at Foundation Medicine where he led the global launch of three products in three years, including the company’s first liquid biopsy offering and the first FDA-approved, CMS-covered, comprehensive genomic profiling companion diagnostic test. Franklin held progressive leadership roles overseeing novel interventional medical devices at Boston Scientific, culminating in his running global strategic planning, product development and marketing for the company’s cardiovascular division. The full text of the announcement from Akili is as follows: Akili Announces Veteran Life Sciences Executive Matt Franklin in Newly Created Role of President and Chief Operating Officer Franklin brings proven track record leading early commercialization and growing disruptive healthcare business models, including at Exact Sciences, Foundation Medicine and Boston Scientific Franklin to oversee Akili’s Commercial, Product, Engineering, Medical and People operations, reporting to CEO Eddie Martucci BOSTON, Mass. – June 6, 2022 – Akili Interactive (“Akili”), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced that industry veteran Matt Franklin will join the company in the newly created role of President and Chief Operating Officer, effective June 21, 2022. “As Akili prepares for the commercialization of our first product later this year, we are thrilled to bring on Matt to help lead us through this pivotal moment in the company’s trajectory,” said Eddie Martucci, CEO and Co-Founder of Akili Interactive. “Matt brings more than two decades of experience leading the development of innovative medical products through launch and commercial growth. Matt is a strong leader of teams and audacious missions, and I am confident that Matt’s commercial and broader operational experience will help propel Akili to its next phase of growth and set us up for long-term success.” As President and COO, Franklin will join Martucci and Akili’s executive leadership team to scale the organization and bring Akili’s diverse pipeline of cognitive treatments to market, with an initial focus on the commercial launch of EndeavorRx®. He will lead the day-to-day operations of the company, and oversee Commercial, Product, Engineering, Medical and People Operations. “I am honored to join Akili, a company with a pioneering mission to deliver clinically-validated software-based therapeutics for patients living with attention dysfunction, a traditionally underserved area of medicine,” said Franklin. “Furthermore, I am excited to build on Akili’s promise to deliver amazing experiences to patients. I look forward to working with Eddie and the rest of the executive team to advance Akili’s pipeline of innovative cognitive medicine.” Franklin brings more than two decades of experience across business, commercial and strategic marketing in the diagnostics, life sciences and technology industries leading and evolving innovation. Most recently, Franklin served as General Manager of the Precision Oncology business unit at Exact Sciences. Previously, Franklin was the Chief Commercial Officer at Thrive Earlier Detection Corp, where he led the go-to-market strategy development for their ground-breaking multi-cancer early detection assay. In addition, Franklin served as the Chief Business Officer for ArcherDX, a growth-stage molecular diagnostics company, where he was responsible for establishing and scaling the global sales, customer support, marketing, market access, business development and corporate development teams. Prior to ArcherDX, Franklin served as the Senior Vice President of Global Marketing and Clinical Product Strategy at Foundation Medicine where he led the global launch of three products in three years, including the company’s first liquid biopsy offering and the first FDA-approved, CMS-covered, comprehensive genomic profiling companion diagnostic test. Franklin held progressive leadership roles overseeing novel interventional medical devices at Boston Scientific, culminating in his running global strategic planning, product development and marketing for the company’s cardiovascular division. Franklin began his career as a technology consultant and software development leader. He holds a B.A. in English literature from Northwestern University, and an M.B.A. from the University of Michigan, Ann Arbor. About Akili Akili is pioneering the development of cognitive treatments through game-changing technologies. Our approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com . Forward-Looking Statements This communication may contain certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding Akili’s expectations for EndeavorRx® and digital medicine, the development of its platform and the launch of EndeavorRx®. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Akili to successfully commercialize EndeavorRx® and continue to advance its clinical development pipeline, (ii) the ability of Akili to maintain relationships with customers and suppliers and retain its management and key employees, (iii) the evolution of the markets in which Akili competes, (iv) the ability of Akili to defend its intellectual property and satisfy regulatory requirements, (v) the impact of the COVID-19 pandemic on Akili’s business, (vi) Akili’s expectations regarding its market opportunities and (vii) the risk of downturns and a changing regulatory landscape in the highly competitive industry in which Akili operates. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Akili assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Akili does not give any assurance that it will achieve its expectations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those statements that relate to Akili’s expectations for EndeavorRx® and digital medicine, the competitive environment in which Akili operates, and Akili and PureTech's future prospects, development plans, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Contacts

  • When was ArcherDx founded?

    ArcherDx was founded in 2013.

  • Where is ArcherDx's headquarters?

    ArcherDx's headquarters is located at 2477 55th Street, Boulder.

  • What is ArcherDx's latest funding round?

    ArcherDx's latest funding round is Acquired - II.

  • How much did ArcherDx raise?

    ArcherDx raised a total of $150M.

  • Who are the investors of ArcherDx?

    Investors of ArcherDx include Invitae, Longwood Fund, PBM Capital Group, Boulder Ventures, Perceptive Advisors and 9 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.